Skip to main content

FDA Licenses GVK's GOSTAR Database for Drug Repurposing Research

Premium

This week, GVK Biosciences said that the US Food and Drug Administration has licensed GOSTAR, a manually curated database of structure-activity relationship, pharmacokinetic, and toxicity data.

GOSTAR contains over 6.5 million manually curated compounds from over 2.5 million patents and 400,000 journals; and more than 18 million quantitative SAR points. It also includes a proprietary drug repurposing platform that pulls in data from other GVK Bio proprietary databases.

GVK Bio said that it will collaborate with the FDA on drug repositioning projects, the first of which will identify alternative therapeutic indications for compounds used to treat neglected and orphan diseases.

The firm will also work with the FDA to enhance GOSTAR's "repositioning and repurposing workflow, and make it available to the entire research community," according to Sreeni Devidas, GVK Bio's vice president of business development.

The financial details of the agreement were not disclosed.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.